UY36010A - NUEVOS COMPUESTOS DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO[3,4-a]PIRAZINA-5,8-DIONA - Google Patents

NUEVOS COMPUESTOS DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO[3,4-a]PIRAZINA-5,8-DIONA

Info

Publication number
UY36010A
UY36010A UY0001036010A UY36010A UY36010A UY 36010 A UY36010 A UY 36010A UY 0001036010 A UY0001036010 A UY 0001036010A UY 36010 A UY36010 A UY 36010A UY 36010 A UY36010 A UY 36010A
Authority
UY
Uruguay
Prior art keywords
new compounds
present
oxazolo
compounds
derivatives
Prior art date
Application number
UY0001036010A
Other languages
English (en)
Inventor
Bruno Artur De Sousa
Carlos Eduardo Da Costa Touzarim
Fabiano Travanca Toledo
Sérgio Luiz Sacurai
Original Assignee
Biolab Sanus Farmacêutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolab Sanus Farmacêutica Ltda filed Critical Biolab Sanus Farmacêutica Ltda
Publication of UY36010A publication Critical patent/UY36010A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevos derivados de 6,7-dihidro-3H-oxazolo[3,4-a]pirazina-5,8-diona o a una mezcla de éstos. La presente invención también contempla composiciones farmacéuticas que comprendan una cantidad eficaz de uno de los nuevos compuestos que son objeto de la presente invención, así como el uso de dichos compuestos y/o derivados como inhibidores de enzimas fosfodiesterasas y el uso de los compuestos y/o derivados en el tratamiento de la disfunción eréctil, de trastornos y/o condiciones tratables con relajación de tejidos y de trastornos tratables con inhibidores de fosfodiesterasas, más específicamente con inhibidores de la PDE-5. Un objetivo adicional de la presente invención es proveer un medicamento que comprenda una cantidad terapéuticamente eficaz de uno de los nuevos compuestos y un método de tratamiento utilizando dichos nuevos compuestos.
UY0001036010A 2014-02-24 2015-02-24 NUEVOS COMPUESTOS DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO[3,4-a]PIRAZINA-5,8-DIONA UY36010A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461943825P 2014-02-24 2014-02-24

Publications (1)

Publication Number Publication Date
UY36010A true UY36010A (es) 2015-09-30

Family

ID=53877456

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036010A UY36010A (es) 2014-02-24 2015-02-24 NUEVOS COMPUESTOS DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO[3,4-a]PIRAZINA-5,8-DIONA

Country Status (19)

Country Link
US (1) US9359378B2 (es)
EP (1) EP3133072B1 (es)
JP (1) JP6636463B2 (es)
KR (1) KR102408431B1 (es)
AR (1) AR099523A1 (es)
AU (1) AU2015221431B2 (es)
BR (1) BR112016019609B1 (es)
CA (1) CA2940225C (es)
CL (1) CL2016002125A1 (es)
ES (1) ES2734063T3 (es)
HU (1) HUE044993T2 (es)
IL (1) IL247330B (es)
MX (1) MX369840B (es)
PL (1) PL3133072T3 (es)
PT (1) PT3133072T (es)
TR (1) TR201910896T4 (es)
UY (1) UY36010A (es)
WO (1) WO2015123748A1 (es)
ZA (1) ZA201606522B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021024894A2 (pt) * 2019-07-15 2022-01-25 Biolab Sanus Farmaceutica Ltda Estereoisômeros do composto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hidroxipropan-2-il)-1-(1h-indol-3-il)-6,7-dihidro-3h-oxazol[3,4-a]pirazina-5,8-diona e seu uso como antitumoral e inibidor da enzima fosfodiesterase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098877A1 (en) * 2001-06-05 2002-12-12 Lilly Icos Llc Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives
AR045950A1 (es) * 2003-10-09 2005-11-16 Speedel Experimenta Ag Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
AR073522A1 (es) * 2008-09-30 2010-11-10 Biolab Sanus Farmaceutica Ltda Compuestos derivados de 2-(3-metilenodioxi) - benzoil indol
BRPI0903803B1 (pt) * 2009-09-30 2019-07-09 Biolab Sanus Farmacêutica Ltda. Composto, processo de preparação, composição farmacêutica e uso dos compostos
UY33535A (es) * 2010-08-13 2011-12-01 Biolab Sanus Farmaceutuca Limitada Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona

Also Published As

Publication number Publication date
EP3133072A1 (en) 2017-02-22
ES2734063T3 (es) 2019-12-04
EP3133072A4 (en) 2017-08-09
PL3133072T3 (pl) 2019-10-31
KR102408431B1 (ko) 2022-06-13
JP6636463B2 (ja) 2020-01-29
HUE044993T2 (hu) 2019-11-28
AU2015221431A1 (en) 2016-09-29
US20150239903A1 (en) 2015-08-27
KR20160116028A (ko) 2016-10-06
CA2940225A1 (en) 2015-08-27
ZA201606522B (en) 2018-04-25
AU2015221431B2 (en) 2018-04-19
PT3133072T (pt) 2019-07-26
AU2015221431A8 (en) 2016-11-24
CL2016002125A1 (es) 2016-12-30
EP3133072B1 (en) 2019-05-01
AR099523A1 (es) 2016-07-27
WO2015123748A1 (pt) 2015-08-27
BR112016019609B1 (pt) 2022-06-14
JP2017506263A (ja) 2017-03-02
MX2016010912A (es) 2016-11-30
TR201910896T4 (tr) 2019-08-21
CA2940225C (en) 2021-12-28
IL247330A0 (en) 2016-09-29
IL247330B (en) 2020-10-29
US9359378B2 (en) 2016-06-07
BR112016019609A2 (es) 2017-08-22
MX369840B (es) 2019-11-22

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
PH12020550857A1 (en) Polycyclic compounds as allosteric shp2 inhibitors
CL2018001624A1 (es) Antagonistas policíclicos del tlr7/8 y uso de los mismos en el tratamiento de trastornos inmunitarios
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
NZ770222A (en) Bicyclic lactams and methods of use thereof
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
MX2019001125A (es) Inhibidores de cinasa macrociclica.
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
ECSP16072941A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201590850A1 (ru) Трициклические конденсированные производные тиофена как ингибиторы jak
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA201692292A1 (ru) Соединения и композиции для стимулирования хондрогенеза
BR112015029989A2 (pt) Uso de dianidrogalactitol e análogos e derivados do mesmo para tratar glioma maligno recorrente ou tumor cerebral secundário progressivo
UY35625A (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
CL2019001092A1 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas.
EA201791030A1 (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
CR20190003A (es) 1H-PIRAZOLO[4,3-b]PIRIDINAS COMO INHIBIDORES DE PDE1
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
EA201692544A1 (ru) 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20230314